Differentiating the HAE crowd
Four companies are vying to bring three different types of treatments to market for hereditary angioedema, and as of last month, all have now reported positive Phase III data. How the products get used is likely to depend in part on how physicians assess the relevance of their targets, as well as on the administration preferences of patients and physicians.
All four products have Orphan Drug designation in the U.S. and the EU, and all could conceivably get to market with Orphan status. Even though Pharming (Euronext:PHARM, Leiden, the Netherlands) and Lev (LEVP,